PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1

NCT ID: NCT01281280

Last Updated: 2014-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-03-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a post-market, open observational long-term effectiveness follow-up study of participants with drug-resistant epilepsy with partial-onset seizures previously enrolled in a randomized controlled trial (PuLsE) comparing Best Medical Practice with or without adjunctive Vagus Nerve Stimulation Therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 2005 Cyberonics, Inc. initiated PuLsE: an open, prospective, randomized, parallel group study directly comparing Best Medical Practice with and without adjunctive VNS Therapy.

In July 2008, the decision was made to discontinue this study due to lower than expected enrolment, impairing the possibility to meet the primary objective with appropriate statistical power. However, the relatively large number of participants (n=121) randomized in the original PuLsE study offers the possibility to generate scientifically valuable and original findings if additional follow-up data can be gathered. After consultation with the PuLsE Investigators, Cyberonics decided to implement an observational long-term follow-up of the participants enrolled in the original PuLsE study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VNS Therapy

No interventions assigned to this group

Best Medical Practice

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible for the study, the participant must meet all the following criteria:

1. Participant must have been randomized in the original PuLsE study.
2. Participant must have baseline data from the original PuLsE study.
3. Participant is able to give accurate seizure counts, health outcomes information, and complete study instruments with minimal assistance.
4. Participant or legal guardian understands study procedures and has voluntarily signed an informed consent for PuLsE 2 in accordance with institutional and local regulatory policies.

Exclusion Criteria

The presence of any of the following will exclude a participant from the study:

1. Participant has a history of non-compliance with the completion of a seizure diary.
2. Participant currently uses, or is expected to use during the study, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.
3. Participant is expected to require full body magnetic resonance imaging during the clinical study.
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cyberonics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Ryvlin, MD

Role: PRINCIPAL_INVESTIGATOR

Unité d'épileptologie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ULB Hopital Erasme

Brussels, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

QE2 Health Sciences Centre Department of Neurology

Halifax, , Canada

Site Status

Hopital Notre Dame

Montreal, , Canada

Site Status

CHU Grenoble

Grenoble, , France

Site Status

Hopital Roger Salengro Service de Neurologie

Lille, , France

Site Status

Hopital Neurologique Unite d' epileptologie

Lyon, , France

Site Status

Hopital Gui De Chauliac

Montpellier, , France

Site Status

Universitatskliniken Bonn

Bonn, , Germany

Site Status

Universitatsklinl Erlangen Zentrum fur Epilepsie

Erlangen, , Germany

Site Status

Azienda Ospedaliero Universitaria

Ancona, , Italy

Site Status

Universita di Bologna

Bologna, , Italy

Site Status

Universita di Pisa

Pisa, , Italy

Site Status

Azienda Ospedialiera "Bianchi Melacrino Morelli"

Reggio Calabria, , Italy

Site Status

Unisersita Cattolica Del Sacro Cuore

Rome, , Italy

Site Status

Centro Epilessia

Torino, , Italy

Site Status

Hans Berger kliniek Neurology

Oosterhout, , Netherlands

Site Status

The National Hospital for Neurology and Neurosurgery

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada France Germany Italy Netherlands United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-101 PuLsE 2

Identifier Type: OTHER

Identifier Source: secondary_id

Epilepsy (E)-101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.